Enanta Pharma Financials - Benzinga

Enanta Pharmaceuticals Inc

ENTANASDAQ

Trade with Public

Trade with Public

$13.16

-0.28-2.08%

At close: Aug 13, 5:00 PM EST

$13.16

-0.28-2.08%

Pre-Market: 4:54 AM EST

Earnings: Q3 2026 Earnings were released on Mon Aug 10th, after the market close

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Enanta Pharma Financials

Enanta Pharma (ENTA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Enanta Pharma Q3 EPS $(0.67) Misses $(0.54) Estimate, Sales $14.359M Miss $16.796M Estimate

Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0.54) by 26.42 percent. This is a 21.18 percent increase over losses of $(0.85) per share from

Benzinga Newsdesk

PRO
Enanta Pharma Q2 EPS $(0.45) Beats $(0.49) Estimate, Sales $17.159M Beat $17.092M Estimate

Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.49) by 8.16 percent. This is a 57.55 percent increase over losses of $(1.06) per share from the

Benzinga Newsdesk

Enanta Pharma Earnings Review: Q1 Summary

Benzinga Insights

PRO
Enanta Pharma Q1 EPS $(0.42) Beats $(0.81) Estimate, Sales $18.615M Beat $16.140M Estimate

Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.81) by 47.96 percent. This is a 60 percent increase over losses of $(1.05) per share from the

Benzinga Newsdesk

Earnings Scheduled For February 9, 2026

Benzinga Insights

Earnings Preview For Enanta Pharma

Benzinga Insights